Table 1.
Agglutination |
FCSA (MFI grading) |
|||||||
Strain | Source | 9da | 9g | STb | 9dc | 9g | Hyp9VG2 | ST |
Reference strains | ||||||||
SSISP 9V/4 | SSI | Y | Y | 9V | + | + | ++ | 9V |
SSISP 9A/1 | SSI | Y | N | 9A | + | ± | + | 9Aα |
SSISP 9N/4 | SSI | N | N | NA | – | – | – | NA |
SSISP 9L/4 | SSI | N | N | NA | – | – | – | NA |
Clinical isolates | ||||||||
AC100 | Hollingshead | Y | Y | 9V | + | + | ++ | 9V |
AC128 | Hollingshead | Y | N | 9A | + | – | – | 9Aβ |
7747 | CDC | Y | Y | 9V | + | + | ++ | 9V |
DS400 | CDC | Y | Y | 9V | + | + | ++ | 9V |
MNZ868 | CDC | Y | N | 9A | + | ± | + | 9Aα |
MNZ869 | CDC | Y | N | 9A | + | – | – | 9Aβ |
MNZ870 | CDC | Y | N | 9A | + | – | – | 9Aβ |
MNZ871 | CDC | Y | N | 9A | + | – | – | 9Aβ |
MNZ873 | CDC | Y | N | 9A | + | – | – | 9Aβ |
MNZ874 | CDC | Y | N | 9A | + | ± | + | 9Aα |
MNZ876 | CDC | Y | Y/N | 9A | + | ± | + | 9Aα |
MNZ877 | CDC | Y | N | 9A | + | – | – | 9Aβ |
MNZ878 | CDC | Y | N | 9A | + | – | – | 9Aβ |
Transformant strains | ||||||||
JC01 | AC100 rpsL::rpsLSr | Y | Y | 9V | + | + | ++ | 9V |
JC02 | JC01 ΔwcjE::JSC | Y | N | 9A | + | – | – | 9Aβ |
MBO1 | JC02 ΔJSC::wcjESSISP9A | Y | N | 9A | + | ± | + | 9Aα |
MBO2 | JC02 ΔJSC::wcjEAC128 | Y | N | 9A | + | – | – | 9Aβ |
MBO4 | JC02 ΔJSC::wcjEMNZ868 | Y | N | 9A | + | ± | + | 9Aα |
Abbreviations: CDC, Centers for Disease Control and Prevention; FCSA, flow-cytometric serotyping assay; Hollingshead, Susan Hollingshead, University of Alabama at Birmingham; MFI, mean fluorescence intensity; NA, not applicable; SSI, Statens Seruminstitut; ST, serotype.
Y, positive agglutination reaction; N, no agglutination; Y/N, 2 of 3 operators graded the reaction as “weak” and the remaining operator graded the reaction as “none.”
Serotype according to the respective assays.
Minus sign, <1-fold MFI increase; plus/minus sign, 1–2-fold MFI increase; plus sign, 2–10-fold MFI increase; 2 plus signs, >10-fold MFI increase.